Enterprise Value
-1.551M
Cash
58.06M
Avg Qtr Burn
-19.52M
Short % of Float
4.59%
Insider Ownership
28.68%
Institutional Own.
39.64%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CT-0525 Details Cancer, Solid tumor/s | Phase 1 Data readout | |
CT-0508 (HER2) + pembrolizumab Details Cancer, Solid tumor/s | Phase 1 Data readout | |
Vicineum™ Details Bladder cancer, Cancer | Failed Discontinued | |
Vicineum™ Details Head and neck squamous cell carcinoma, Cancer | Failed Discontinued | |
CT-0508 (HER2) Details Solid tumor/s, Cancer | Failed Discontinued |